Results from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly reduced spleen volume in patients with myelofibrosis.

Good morning, and welcome to Sarepta's preliminary data readout of its Phase I/II studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to ...

That's because "robot umpires," in a sense, have officially arrived to MLB. The human element remains, but players will now ...